BMS and Wyeth are two of the latest to have noticed Solvay’s unusually healthy pipeline. The mid-sized group’s new dealmaking drive means they’re unlikely to be the last.
By Melanie Senior
It's hardly surprising that much of the biopharma industry hasn't even heard of Belgium's Solvay SA . For one,...
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
Rising Leader Abbas Kazimi's leadership at Nimbus Therapeutics combines immigrant resilience, patient-first partnerships, contrarian strategic bets and a deeply personal mission driving breakthrough drug discovery innovation.
Trojan Bio’s proprietary platform, based on engineered antibodies that activate the immune system to fight cancer in the same way as common viral infections, won Biomed Israel's 2025 biopharma start-up award. CEO and cofounder Anat Burkovitz said the technology is attracting investors' attention.
